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Abstract
Background: Measures of bacillary load in patients with tuberculosis (TB) may be useful for predicting and monitoring
response to treatment. The relationship between quantitative T-cell responses and mycobacterial load remains unclear. We
hypothesised that, in a HIV-prevalent high burden setting, the magnitude of mycobacterial antigen-specific and non-
specific T-cell IFN-c responses would correlate with (a) bacterial load and (b) culture conversion in patients undergoing
treatment.
Methods:We compared baseline (n = 147), 2 (n = 35) and 6 month (n = 13) purified-protein-derivative (PPD) and RD1-specific
(TSPOT.TB and QFT-GIT) blood RD1-specific (TSPOT.TB; QFT-GIT) responses with associates of sputum bacillary load in
patients with culture-confirmed TB in Cape Town, South Africa.
Results: IFN-c responses were not associated with liquid culture time-to-positivity, smear-grade, Xpert MTB/RIF-generated
cycle threshold values or the presence of cavities on the chest radiograph in patients with culture-confirmed TB and
irrespective of HIV-status. 2-month IGRA conversion rates (positive-to-negative) were negligible [,11% for TSPOT.TB (3/28)
and QFT-GIT (1/29)] and lower compared to culture [60% (21/35); p,0.01].
Conclusions: In a high burden HIV-prevalent setting T-cell IFN-c responses to M. tuberculosis-specific and non-specific
antigens do not correlate with bacillary load, including Xpert MTB/RIF-generated CT values, and are therefore poorly suited
for monitoring treatment and prognostication.
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Introduction
Measures of bacillary load at diagnosis or after the intensive
phase of anti-TB treatment are crudely associated with relapse and
treatment failure in tuberculosis (TB) patients, yet better and more
accurate prognostic and treatment monitoring tools are needed
[1]. Such tools may identify high risk patients and facilitate the
more rapid evaluation of new therapeutic interventions for TB. It
has been suggested that immunodiagnostic biomarkers such as
interferon-c (IFN-c) release assays (IGRAs) may serve as surrogate
markers of bacillary load and treatment response [2]. Although the
diagnostic accuracy of standardised IGRAs [TSPOT.TB (Oxford
Immunotec, UK) and QuantiFERON TB Gold-in-tube (QFT-
GIT; Cellestis, Australia)] for latent and active TB have been
extensively studied [3–9], there are hardly any data about their
relationship with bacterial load [10]. The relationship between
bacillary burden and the magnitude of IFN-c in response to RD-1
specific antigens thus remains uncertain [11]. Their role as tools of
prognostication and disease monitoring have also been little
studied, particularly in high burden settings.
A previous study performed in a small number of HIV-infected
TB patients demonstrated a crude relationship between antigen-
specific T-cell responses and sputum bacillary load [10]. This
finding is supported by the longitudinal increase in quantitative
IFN-c responses in TB contacts prior to diagnosis with active TB
[12,13], as well as declining IFN-c responses seen in TB patients in
low burden settings undergoing treatment [14–16]. This latter
aspect remains inconsistent, however, as several studies have
reported persistently increased positive responses during and after
treatment [17–25]. Thus, the role of IGRAs as tools of
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prognostication and disease monitoring continues to remain
unclear, especially with regard to their utility in high burden
settings. Evaluating the relationship between quantitative T-cell
responses using both standardised IGRAs (TSPOT.TB and QFT-
GIT) and bacillary load at diagnosis or during treatment has
hitherto not been undertaken. These aspects are also largely
unexplored with regard to non-specific antigens such as M.
tuberculosis-derived purified protein derivative (PPD) and newer
measures of bacillary load [such as the World Health Organisa-
tion-recommended Xpert MTB/RIF assay [26]].
To address these gaps in our knowledge we comparatively
evaluated the magnitude of Th1-based M. tuberculosis-specific and
non-specific quantitative T cell responses with measures of sputum
bacillary load, some of which are known to be associated with
treatment outcomes, prior to and during treatment in TB patients
from Cape Town, South Africa.
Materials and Methods
Study Population
Sputa and blood were collected at the time of diagnosis from
513 consecutively recruited ambulatory patients with suspected
TB ($18 years of age) between February 2007 and April 2010 at
two primary care clinics in Cape Town, South Africa (Figure 1).
Informed written consent was obtained from all participants and
the study was approved by the University of Cape Town, Faculty
of Health Sciences Research Ethics Committee. Detailed patient
and laboratory-specific information were recorded on a standard-
ized case record form and captured using double data entry.
Patient Flow and Diagnostic Tests
All patients had at least one concentrated fluorescent smear and
one BACTEC MGIT 960 (BD Diagnostics, USA) liquid culture
performed on spot or morning sputum (Figure 1). Culture
positivity for M. tuberculosis served as a reference standard for
definite TB. An HIV test was performed after appropriate
counselling. When available, a sputum sample was archived and
later used for Xpert MTB/RIF (Cepheid, Sunnyvale, USA) testing
[27]. Blood was collected at recruitment and used for the
TSPOT.TB, QFT-GIT and PPD enzyme-linked immunosorbent
spot (ELISPOT) assays. Where possible, a chest X-ray [CXR; read
by 2 readers blinded to clinical information using the validated
CXR scoring and recording system (CRRS) [28,29]] was
performed at recruitment. 35 randomly selected TB patients
received, in addition to routine follow-up smear microscopy and
culture, a TSPOT.TB, QFT-GIT and PPD ELISPOT test at 2
months post-treatment initiation. 13 of these patients received
these tests again at 6 months. The accuracy of TSPOT.TB, QFT-
GIT, Xpert MTB/RIF and CRRS for the diagnosis of TB in this
cohort has previously been published [8,27,30,31].
Interferon-c Release Assays
All tests were performed according to the manufacturers’
instructions on blood by laboratory technicians blinded to patient
information. PBMCs were isolated from the blood and each IGRA
performed within 8 hours of venepuncture. TSPOT.TB, QFT-
GIT and PPD ELISPOT results were reported and interpreted as
described previously [8,32].
Data Analysis
Culture positivity for M. tuberculosis from at least a single sample
served as a reference standard for definite TB. Statistical analyses
were performed using Graphpad Prism (version 5.0; GraphPad
Software, San Diego, USA, www.graphpad.com) and OpenEpi
(version 2.3.1) [33]. Statistical tests on longitudinal changes in
IFN-c levels were done on a per patient basis. TSPOT.TB and
QFT-GIT results defined as indeterminate according to the
manufacturers’ definitions were excluded. All data was also
analysed stratified by HIV status.
Results
Baselines Characteristics of Study Population
Table 1 and Figure 1 show the baseline characteristics of the
cohort. Of the 513 participants, 63% (354/513) were male and
26% (133/445) were HIV-infected. 29% (147/513) of participants
had definite TB, 67% (98/147) of whom were smear-positive. TB
patients were significantly more likely to be younger (p,0.01), of
black (p,0.01) or mixed ancestry (p,0.01), have a history of
previous TB (p = 0.02), HIV-infected (p,0.05) and TSPOT.TB-
(p,0.01) or QFT-GIT-positive (p,0.01).
Correlation of Interferon-c Responses with Liquid Culture
Median IFN-c responses differed significantly in culture-positive
vs. -negative individuals when measured using TSPOT.TB [111
(IQR: 500-194) vs. 32 (10–104) SFC?1026 PBMCs; p,0.01] and
QFT-GIT [2.2 (0.6, 5.2) vs. 0.7 (0.1, 3.1) international units
(IU)?ml21; p,0.01], but not in response to PPD [100 (36, 161) vs.
86 (16, 157) SFC?1026 PBMCs; p = 0.28]. On average, the
magnitude of IFN-c response decreased with increasing TTP in
individuals with definite TB, however, this did not reach
significance [p-value; Spearman’s rank correlation coefficient
(rS)] for TSPOT.TB (0.11; 20.14), QFT-GIT (0.07; 20.16) or
PPD ELISPOT (0.09; 20.15) (Figure 2).
Correlation of Interferon-c Responses with Smear Status
and Grade
Median IFN-c responses did not differ significantly in individ-
uals with smear-positive vs. -negative definite TB [114 (IQR: 63-
208) vs. 92 (30, 172) SFCN1026 PBMCs for TSPOT.TB (p = 0.12);
2.3 (0.7–5.5) vs. 1.6 (0.4–4.8) IU?ml21 for QFT-GIT (p = 0.14);
100 (51–158) vs. 99 (18–151) SFC?1026 PBMCs for PPD
(p = 0.39)]. IFN-c responses did not significantly correlate with
increasing smear grade for either assay (p-values for T.SPOT.TB,
QFT-GIT and PPD of 0.42, 0.09, and 0.85, respectively)
(Figure 2).
Correlation of Interferon-c Responses with Xpert MTB/RIF
Performance
Median IFN-c responses differed significantly in Xpert MTB/
RIF-positive (130/480) vs. Xpert MTB/RIF-negative (350/480)
individuals when measured using the TSPOT.TB [109 (IQR: 49–
206) vs. 40 (10–115) SFC?1026 PBMCs; p,0.01] and QFT-GIT
assays [2.2 (0.6–5.4) vs. 0.7 (0.1–3.1) IU?ml21; p,0.01], but not in
response to PPD [100 (45–160) vs. 91 (17–185) SFC?1026 PBMCs;
p = 0.21]. On average, IFN-c responses decreased with increasing
Xpert MTB/RIF-generated cycle threshold (CT) values in Xpert
MTB/RIF-positive individuals with definite TB, however, this
relationship was not significant (p-value; rS) for TSPOT.TB (0.70;
20.04), QFT-GIT (0.91; 0.01) or PPD ELISPOT (0.49; 20.07)
(Figure 2).
Correlation of Interferon-c Responses with Chest
Radiography Data
IFN-c responses differed significantly in individuals who had
CXR suspicious of active TB (344/416) vs. those who had
a normal CXR (72/416), when measured using TSPOT.TB [58
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(IQR: 15–153) vs. 31 (8–101) SFC?1026 PBMCs; p,0.01] and
QFT-GIT assays [1.1 (0.2–4.6) vs. 0.3 (0.0–2.3) IU?ml21;
p,0.01], but not in response to PPD [96 (28–180) vs. 92 (20–
142) SFC?1026 PBMCs; p = 0.37]. In patients with definite TB
who had a CXR compatible with active disease, median IFN-c
responses did not differ significantly between those who had
cavities (52/124) and those who did not (72/124) when measured
using TSPOT.TB [140 (80–208) vs. 112 (33–190) SFC?1026
PBMCs; p = 0.12], QFT-GIT [3.0 (1.0–5.8) vs. 1.6 (0.4–4.6)
IU?ml21; p.0.05] or PPD ELISPOT [106 (28–194) vs. 117 (34–
159) SFC?1026 PBMCs; p = 0.88].
Impact of HIV-status on Interferon-c Response
HIV-infected patients with definite TB had a similar IFN-c
response compared to those without HIV-infection when mea-
sured using the TSPOT.TB assay [86 (IQR: 31–158) vs. 115 (56–
200); p = 0.22], but when measured using QFT-GIT [2.2 (0.4–3.8)
vs. 3.7 (0.9–6.1); p = 0.02] or the PPD ELISPOT [62 (20–118) vs.
122 (62–196); p,0.01] the magnitude of response was significantly
lower in the HIV-infected group. When the definite TB group was
stratified by HIV-status, the correlation between IFN-c response
and bacterial load proxy [for each marker (including cavitation)
Figure 1. Patient flow diagram and diagnostic outcomes stratified by final diagnostic category. *128 patients had no chest X-ray data.
{To be eligible for the study, patients needed to provide at least 2 sputum samples (spot or morning), both of which were used for concentrated
fluorescent smear microscopy and liquid culture. When available, a paired second spot sputum sample was collected and archived. This was later
used for Xpert MTB/RIF testing (n = 389). {The TSOT.TB, QFT.GIT and the PPD ELISPOT tests were not all concurrently available throughout the
duration of study and thus not all patients necessarily received a combination of all 3 IGRAs. The number of valid results for TSPOT.TB, QFT-GIT and
PPD respectively were 457, 457, and 462, respectively. 9 TSPOT.TB indeterminate results and 52 indeterminate QFT-GIT results occurred and are
excluded. Only patients with culture-confirmed TB were included in the main analysis for the comparison of IGRA-response with bacterial load.
doi:10.1371/journal.pone.0037436.g001
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and for each IGRA] was non-significant, irrespective of HIV-
status (data not shown).
Smear- and Culture-status of Patients Undergoing
Treatment
The status of the 35 culture-positive patients who were available
for IGRA-based follow-up is shown in Table 2. After 2 months of
anti-TB therapy, 60% (21/35) of these individuals had culture-
converted and were identified as responders to therapy.
Longitudinal Changes in Interferon-c Release Assay
Status
11% (3/28) of individuals who were TSPOT.TB-positive at
0 months were negative at 2 months and 5% (1/29) of individuals
with TB who were QFT-GIT-positive at 0 months were negative
at 2 months (Table 2). In contrast, 63% (15/24) of smear-positive
individuals at 0 months were negative at 2 months (p-values of
,0.01 and ,0.01 compared to TSPOT.TB and QFT-GIT,
respectively). 60% (21/35) of culture-positive individuals at
0 months were negative at 2 months (p-values of ,0.01 and
,0.01 compared to TSPOT.TB and QFT-GIT, respectively). At
6 months, the proportions of patients who had converted were 8%
(1/13) and 30% (3/11) for TSPOT.TB and QFT-GIT re-
spectively.
Longitudinal Changes in Quantitative Interferon-c
Responses
Quantitative IFN-c responses to RD-1 specific antigens or
PPD did not change on a per patient basis between 0 vs. 2
months (p-values of 0.51, 0.88 and 0.26 for TSPOT.TB, QFT-
GIT and PPD, respectively) or between 0 vs. 6 months (p-values
of 0.83, 0.32, and 0.11 for each test) in individuals with definite
TB (Figure 3). There was also no significant longitudinal change
in per patient IFN-c levels across all 3 time points (p-values of
0.69, 0.06 and 0.13 for each test respectively). Furthermore, no
longitudinal changes in IFN-c response were detected in
individuals who culture converted at 2 months, irrespective of
the type of IGRA used (p-values of 0.27, 0.60, and 0.22
respectively for individuals culture-negative at 2 months; p-values
of 0.08, 0.24 and 1.00 for TSPOT.TB, QFT-GIT and PPD
respectively for individuals still culture-positive at 2 months)
Table 1. Demographic and clinical characteristics of patients stratified by culture status.








Mean years (range) 39 (18–83) 37 (19–71) 39 (18–83) ,0.05
Sex
Male 354 (69) 93 (63) 255 (71) 0.10
Female 159 (31) 54 (37) 105 (29) -
Race
Black 363 (71) 109 (74) 250 (69) 0.24
Mixed ancestry (coloured) 140 (27) 36 (25) 103 (29) 0.38
White 10 (2) 2 (1) 10 (2) 0.39
Previous tuberculosis
Yes 172 (34) 38 (26) 132 (37) 0.02
No 321 (63) 102 (69) 215 (60) 0.04
Unknown 20 (4) 7 (5) 13 (4) 0.55
HIV-infected
Yes 133 (26) 47 (32) 85 (24) 0.06
No 312 (61) 85 (58) 224 (62) 0.62
Unknown 68 (13) 10 (4) 51 (14) 0.02
CD4 count (cells/ml) (range){ 198 (7–935) 199 (7–894) 192 (14–935) 0.10
TSPOT.TB
Positive 297 (58) 115 (78) 180 (50) ,0.01
Negative 160 (31) 18 (12) 138 (38) ,0.01
Indeterminate 9 (2) 1 (1) 8 (2) 0.26
Unknown 47 (31) 13 (9) 34 (9) 0.84
QFT-GIT
Positive 311 (61) 111 (76) 196 (54) ,0.01
Negative 146 (28) 19 (13) 40 (11) ,0.01
Indeterminate 52 (10) 15 (10) 36 (10) 0.93
Unknown 4 (1) 2 (1) 2 (1) 0.41
*6 patients did not have a useable culture result (culture contaminated) and were excluded.
{Performed if HIV-infected. Excludes 8 patients with no CD4 count data.
doi:10.1371/journal.pone.0037436.t001
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(Table 3). IFN-c responses also did not differ in culture-negative
vs. –positive individuals at this time point [96 (IQR: 24-164) vs.
136 (77 vs. 210) SFC?1026 PBMCs for TSPOT.TB (p = 0.21),
3.2 (0.0–8.9) vs. 1.3 (0.3–4.4) for QFT-GIT (p = 0.78), and 93
(50–125) vs. 96 (51–166) for PPD (p = 0.67)] nor were there any
differences in baseline IFN-c response between 2 month culture
converters and non-converters [110 (34–207) vs. 76 (4 vs. 98)
SFC?1026 PBMCs for TSPOT.TB (p = 0.10), 2.2 (0.4–4.9) vs.
4.2 (0.5–5.3) for QFT-GIT (p = 0.63), and 122 (27–161) vs. 81
(27–157) for PPD (p = 0.57)].
At 6 months post-treatment initiation IFN-c levels did not
change significantly from diagnosis in individuals who had
culture-converted (p-values of 1.00, 0.08 and 0.46 for
TSPOT.TB, QFT-GIT and PPD respectively). Due to the small
number of culture-positive TB cases after 6 months of treatment
(n = 3), we were unable to conclusively compare differences in
IFN-c responses between converters and non-converters at this
time point, however, all 3 6 month non-converters were
TSPOT.TB- and QFT-GIT-positive.
Discussion
It has been suggested that IFN-c responses to RD1-specific and
non-specific antigens may be useful as prognostic tools, and for
monitoring bacterial load and treatment response [2]. However,
there is limited information from high-burden settings. Our main
aim was to evaluate, at diagnosis, the relationship between IGRAs
and measures of bacterial load, which is a prognostic tool
associated with treatment failure [1], in patients with TB. We
further comparatively evaluated one in-house and two standar-
dised IGRAs longitudinally in relation to 2-month culture
conversion, a measure known to be associated with treatment-
related outcome [1].
The key findings of our study were: (i) T-cell IFN-c responses do
not correlate with measures of bacterial load in TB patients at
Figure 2. IFN-c responses measured using the TSPOT.TB, QFT-GIT and PPD ELISPOT assays and correlated with liquid culture time-
to-positivity, smear status and grade, and Xpert MTB/RIF-generated CT values in individuals with culture-confirmed TB. Culture,
smear-microscopy and the Xpert MTB/RIF assay were performed on a paired sputum sample collected at diagnosis. P-values and Spearman’s rank
correlation coefficient (rS) are shown where appropriate. Abbreviations: SFC, spot-forming colonies; IFN-c, interferon–c; QFT-GIT, QuantiFERON TB
Gold-in-tube; ELISPOT, enzyme-linked immunosorbent spot; PBMCs, peripheral blood mononuclear cells; IU, international units; TTP, time-to-
positivity; CT, cycle threshold.
doi:10.1371/journal.pone.0037436.g002
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diagnosis including culture TTP, smear status and grade, Xpert
MTB/RIF CT values, or the presence of cavities on the CXR and
this occurred irrespective of HIV status; (ii) IFN-c levels (whether
in response to the RD1-specific antigens or PPD) do not change
significantly after 2 or 6 months of anti-TB treatment, irrespective
of culture conversion status.
We did not detect any relationship between quantitative IFN-c
responses and bacillary load at diagnosis irrespective of HIV
status. By contrast, a smaller study in HIV-infected TB patients in
similar setting found a significant but weak correlation between
quantitative TSPOT.TB responses and smear grade (a relatively
crude measure of bacterial load) but none with culture TTP [10].
Cavitation on the radiograph, previously shown to be associated
with either significantly elevated sputum bacillary load or RD1-
specific responses in low burden settings [21,34], was not
associated with elevated IFN-c responses in our study. There is,
Table 2. Status of TB patients at diagnosis (all culture-positive) and after 2 and 6 months of anti-TB treatment.
Months of anti-TB treatment
0 months (n=35) 2 months (n =35) 6 months (n=13)
Converters (%) (from positive at 0 months to
negative at 2 or 6 months)
Smear microscopy* N/A 63 (15/24) 100 (9/9)
Liquid culture N/A 60 (21/35) 77 (10/13)
TSPOT.TB{ N/A 11 (3/28) 8 (1/13)
QFT-GIT{ N/A 5 (1/29) 30 (3/11)
Median IFN-c response1 (IQR)
TSPOT.TB (SFC?1026 PBMCs) 94 (35–158) 118 (57–174) (p = 0.51) 111 (50–310) (p = 0.83)
QFT-GIT (IU?ml21) 2.8 (0.6–4.9) 2.5 (0.2–7.2) (p = 0.88) 0.9 (0.0–7.6) (p = 0.32)
PPD (SFC?1026 PBMCs) 100 (30–153) 90 (46–127) (p = 0.26) 136 (96–309) (p = 0.11)
*Of the 24/35 individuals who were smear-positive at 0 months, 15/24 had converted at 2 months. Of 13 individuals followed up at 6 months, 9 were smear-positive at
month 0 and all 9 had converted at 6 months.
{Of the 28/35 individuals who were TSPOT.TB-positive at 0 months, 3/28 had converted at 2 months. All 13 individuals at month 6 were TSPOT.TB-positive month 0.
{Of the 29/35 individuals who were QFT-GIT-positive at 0 months, 1/29 had converted at 2 months. 11 of the 13 individuals followed up at month 6 were QFT-GIT-
positive at month 0. 2/35 individuals had an indeterminate QFT-GIT result at month 0.
1Per patient p-values are shown for comparisons of IFN each IGRA for either 2 or 6 months vs. 0 months.
Abbreviations: SFC, spot forming colonies; PBMCs, peripheral blood mononuclear cells; IU, international units.
doi:10.1371/journal.pone.0037436.t002
Figure 3. Longitudinal IFN-c responses are shown for patients undergoing anti-TB treatment at 2 months (n=35) and 6 months
(n=13). Capped horizontal bars represent the median IFN-c response at each time-point.
doi:10.1371/journal.pone.0037436.g003
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to the best of our knowledge, no published literature on the
correlation of IFN-c responses with Xpert MTB/RIF CT values.
The poor relationship between IFN-c response and bacillary load
may be a function of T cell compartmentalisation and immuno-
suppressive mediators including IL-10, TGF-b and regulatory
T cells [35,36]. Thus, TB-specific T cells are concentrated in the
lung and not in the sampled compartment, and those with the
most extensive disease may have the greatest attenuation of RD-1-
specific Th1 immunity. Whether other antigens such as HBHA
behave differently remains unclear [37–40].
Are serial IFN-c responses useful for monitoring patient-related
outcomes in TB patients undergoing treatment? A comparative
analysis of the different IGRA formats for treatment monitoring
(or correlation of initial bacillary load) has not previously been
undertaken. The majority of studies that have examined longitu-
dinal IGRA responses have been performed in a low burden
setting [17,19,23,24]. In our study, and similar to findings in The
Gambia where an in-house assay was used [25], standardised IFN-
c responses to both RD1-specific antigens and PPD did not
appreciably change longitudinally. Although the sensitivity of the
T-SPOT and QFT-GIT assays are known to differ [6] we found
no differences in the longitudinal readouts. In contrast to
a previous study which found that RD-1, but not PPD responses,
selectively diminished during the course of treatment [16] we
found that responses to both antigens remained persistently
elevated. Of note, however, is that this earlier study used an in-
house experimental assay which, in contrast to the commercially
available TSPOT.TB or QFT-GIT tests, utilised two ESAT-6-
derived peptides. This, rather than setting-specific differences with
our study, might account for these discordant results, especially
given that the findings of the original study have since been
confirmed in India, where a similar assay was used [41].
Given the poor correlation we found between IFN-c responses
and culture TTP and cavitation at diagnosis, both of which are
known associates of 2-month culture conversion [34,42–45]; it is
unsurprising that we also detected no association between IFN-c
responses and this outcome. This high proportion of persistent T-
cell responses may be due to several factors including: a history of
repeated or on-going TB exposure in a high burden environment,
the slow decay kinetics of T cells [24,46], or greater T cell
stimulation with antigen release during the course of treatment.
Indeed, history of past-exposure is likely to cause an initially high
IFN-c response which, in patients with latent TB, has shown to
remain largely unchanged throughout chemotherapy [46].
There are several limitations to this study. Firstly, all patients
did not receive the same combination of tests due to the study
design. Although this restricted our sample size, our study
nonetheless remains the largest that has specifically looked at the
issue of IFN-c responses and bacillary load. Second, only a subset
of patients underwent 6 month follow-up and, as a result, the
conclusiveness of our findings limited. Third, given the relatively
high prevalence of TB and HIV co-infection in South Africa, these
findings may not be generalizable to other settings. Fourth, the
Xpert MTB/RIF assay in this cohort was performed on archived
sputum samples, which may influence the CT values generated by
the assay, however, this effect has previously not shown to be
significant [27,47]. Finally, it is worth noting that culture
conversion itself correlates only crudely with unfavourable
treatment outcomes [1] but nevertheless remains the best
surrogate biomarker of treatment outcome.
In conclusion, our data suggest that T-cell IFN-c responses to
either RD1-specific or non-specific antigens do not correlate with
bacillary burden or treatment outcome amongst TB patients in
a high burden setting. They are hence unlikely to have utility as
prognostic tools at initial evaluation or to monitor either disease
severity or treatment response.
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